Treating bacterial pneumonia in people living with HIV

References

• Afessa B, Green W, Chiao J, et al. Pulmonary complications of HIV infection: autopsy findings. Chest. 1998;113(5):1225–1229.
   PubMed Web of Science ®Google Scholar
• Masliah E, DeTeresa RM, Mallory ME, et al. Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS. 2000;14(1):69–74.
   PubMed Web of Science ®Google Scholar
• Huang L, Crothers KA. HIV-associated opportunistic pneumonias. Respirology. 2009;14(4):474–485.
   PubMed Web of Science ®Google Scholar
• Turett GS, Blum S, Telzak EE. Recurrent pneumococcal bacteremia: risk factors and outcomes. Arch Internal Med. 2001;161(17):2141–2144.
   PubMedGoogle Scholar
• Figueiredo-Mello C, Naucler P, Negra MD, et al. Prospective etiological investigation of community-acquired pulmonary infections in hospitalized people living with HIV. Medicine (Baltimore). 2017;96(4):e5778.
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Gerstoft J, et al. Hospitalization for pneumonia among individuals with and without HIV infection, 1995–2007: a Danish population-based, nationwide cohort study. Clin Infect Dis. 2008;47(10):1345–1353.
   PubMed Web of Science ®Google Scholar
• Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med. 2011;183(3):388–395.
   PubMed Web of Science ®Google Scholar
• Crothers K, Thompson BW, Burkhardt K, et al. HIV-associated lung infections and complications in the era of combination antiretroviral therapy. Proc Am Thorac Soc. 2011;8(3):275–281.
   PubMedGoogle Scholar
• Murray JF. Epidemiology of human immunodeficiency virus-associated pulmonary disease. Clin Chest Med. 2013 Jun;34(2):165–179.
   PubMed Web of Science ®Google Scholar
• Almeida A, Boattini M. Community-acquired pneumonia in HIV-positive patients: an update on etiologies, epidemiology and management. Curr Infect Dis Rep. 2017;19(1):2.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Chene G, Thiebaut R, et al. Trends and determinants of severe morbidity in HIV-infected patients: the ANRS CO3 Aquitaine Cohort, 2000–2004. HIV Med. 2007;8(8):547–554.
   PubMed Web of Science ®Google Scholar
• Attia EF, McGinnis KA, Feemster LC, et al. Association of COPD with risk for pulmonary infections requiring hospitalization in HIV-infected Veterans. J Acquired Immune Deficiency Syndromes (1999). 2015;70(3):280–288.
   PubMed Web of Science ®Google Scholar
• Sarkar P, Rasheed HF. Clinical review: respiratory failure in HIV-infected patients–a changing picture. Crit Care. 2013;17(3):228.
   PubMed Web of Science ®Google Scholar
• Gingo MR, Morris A. Pathogenesis of HIV and the lung. Curr HIV/AIDS Rep. 2013;10(1):42–50.
   PubMed Web of Science ®Google Scholar
• Malinis M, Myers J, Bordon J, et al. Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumonia. Int J Infect Dis. 2010;14(1):e22–7.
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Torres A, Manzardo C, et al. Community-acquired pneumococcal pneumonia in virologically suppressed HIV-infected adult patients: a matched case-control study. Chest. 2017;152(2):295–303.
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Torres A, Polverino E, et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. Eur Respir J. 2014;43(6):1698–1708.
   PubMed Web of Science ®Google Scholar
• Feikin DR, Feldman C, Schuchat A, et al. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis. 2004;4(7):445–455.
   PubMed Web of Science ®Google Scholar
• Segal LN, Methe BA, Nolan A, et al. HIV-1 and bacterial pneumonia in the era of antiretroviral therapy. Proc Am Thorac Soc. 2011;8(3):282–287.
   PubMedGoogle Scholar
• Sogaard OS, Reekie J, Ristola M, et al. Severe bacterial non-aids infections in HIV-positive persons: incidence rates and risk factors. J Infect. 2013;66(5):439–446.
   PubMed Web of Science ®Google Scholar
• Le Moing V, Rabaud C, Journot V, et al. Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV-infected patients started on a protease inhibitor-containing regimen. HIV Med. 2006;7(4):261–267.
   PubMed Web of Science ®Google Scholar
• Bénard A, Mercié P, Alioum A, et al. Bacterial pneumonia among HIV-infected patients: decreased risk after tobacco smoking cessation. ANRS CO3 Aquitaine Cohort, 2000–2007. PLoS One. 2010;5(1):e8896.
   PubMed Web of Science ®Google Scholar
• O’Connor J, Vjecha MJ, Phillips AN, et al. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per muL: secondary outcome results from a randomised controlled trial. Lancet HIV. 2017;4(3):e105–e112.
   PubMed Web of Science ®Google Scholar
• Gordin FM, Roediger MP, Girard P-M, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008;178(6):630–636.
   PubMed Web of Science ®Google Scholar
• Jamal A, Phillips E, Gentzke AS, et al. Current cigarette smoking among adults — United States, 2016. Morbidity Mortality Weekly Rep. 2018;67(2):53–59.
   PubMed Web of Science ®Google Scholar
• Crothers K, Goulet JL, Rodriguez-Barradas MC, et al. Impact of cigarette smoking on mortality in HIV-positive and HIV-negative veterans. AIDS Educ Prev. 2009;21(3 Suppl):40–53.
   PubMed Web of Science ®Google Scholar
• Crothers K, Griffith TA, McGinnis KA, et al. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20(12):1142–1145.
   PubMed Web of Science ®Google Scholar
• Helleberg M, May MT, Ingle SM, et al. Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS. 2015;29(2):221–229.
   PubMed Web of Science ®Google Scholar
• Brune KA, Ferreira F, Mandke P, et al. HIV impairs lung epithelial integrity and enters the epithelium to promote chronic lung inflammation. PLoS One. 2016;11(3):e0149679.
   PubMed Web of Science ®Google Scholar
• Clarke JR, Taylor IK, Fleming J, et al. The epidemiology of HIV-1 infection of the lung in AIDS patients. AIDS. 1993;7(4):555–560.
   PubMed Web of Science ®Google Scholar
• Chinnapaiyan S, Dutta R, Bala J, et al. Cigarette smoke promotes HIV infection of primary bronchial epithelium and additively suppresses CFTR function. Sci Rep. 2018;8(1):7984.
   PubMedGoogle Scholar
• Nieman RB, Fleming J, Coker RJ, et al. The effect of cigarette smoking on the development of AIDS in HIV-1-seropositive individuals. AIDS. 1993;7(5):705–710.
   PubMed Web of Science ®Google Scholar
• Feldman JG, Minkoff H, Schneider MF, et al. Association of cigarette smoking with HIV prognosis among women in the HAART era: a report from the women’s interagency HIV study. Am J Public Health. 2006;96(6):1060–1065.
   PubMed Web of Science ®Google Scholar
• Winhusen T, Feaster DJ, Duan R, et al. Baseline cigarette smoking status as a predictor of virologic suppression and CD4 cell count during one-year follow-up in substance users with uncontrolled HIV infection. AIDS Behav. 2018;22(6):2026–2032.
   PubMed Web of Science ®Google Scholar
• Brown JL, Winhusen T, DiClemente RJ, et al. The association between cigarette smoking, virologic suppression, and CD4+ lymphocyte count in HIV-Infected Russian women. AIDS Care. 2017;29(9):1102–1106.
   PubMed Web of Science ®Google Scholar
• Akhtar-Khaleel WZ, Cook RL, Shoptaw S, et al. Trends and predictors of cigarette smoking among HIV seropositive and seronegative men: the multicenter aids Cohort study. AIDS Behav. 2016;20(3):622–632.
   PubMed Web of Science ®Google Scholar
• De P, Farley A, Lindson N, et al. Systematic review and meta-analysis: influence of smoking cessation on incidence of pneumonia in HIV. BMC Med. 2013;11(1):15.
   PubMedGoogle Scholar
• Pett SL, Carey C, Lin E, et al. Predictors of bacterial pneumonia in evaluation of subcutaneous interleukin-2 in a randomized international trial (ESPRIT). HIV Med. 2011;12(4):219–227.
   PubMed Web of Science ®Google Scholar
• Bassetti S, Battegay M. Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies. Infection. 2004;32(3):163–169.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Gordon KS, Crothers K, et al. Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIVAssociation of prescribed opioids with risk of community-acquired pneumonia in patients with HIVAssociation of prescribed opioids with risk of community-acquired pneumonia in patients with HIV. JAMA Intern Med. 2019;179(3):297–304.
   PubMed Web of Science ®Google Scholar
• Beck JM. Abnormalities in host defense associated with HIV infection. Clin Chest Med. 2013;34(2):143–153.
   PubMed Web of Science ®Google Scholar
• Shellito JE. Failure of host defenses in human immunodeficiency virus. Semin Respir Crit Care Med. 2004;25(1):73–84.
   PubMed Web of Science ®Google Scholar
• McCune JM. The dynamics of CD4+ T-cell depletion in HIV disease. Nature. 2001;410:974.
   PubMed Web of Science ®Google Scholar
• Brenchley JM, Knox KS, Asher AI, et al. High frequencies of polyfunctional HIV-specific T cells are associated with preservation of mucosal CD4 T cells in bronchoalveolar lavage. Mucosal Immunol. 2008;1(1):49–58.
   PubMed Web of Science ®Google Scholar
• Knox KS, Vinton C, Hage CA, et al. Reconstitution of CD4 T cells in bronchoalveolar lavage fluid after initiation of highly active antiretroviral therapy. J Virol. 2010;84(18):9010–9018.
   PubMed Web of Science ®Google Scholar
• Jambo KC, Sepako E, Fullerton DG, et al. Bronchoalveolar CD4(+) T cell responses to respiratory antigens are impaired in HIV-infected adults. Thorax. 2011;66(5):375–382.
   PubMed Web of Science ®Google Scholar
• Collini PJ, Bewley MA, Mohasin M, et al. HIV gp120 in the lungs of antiretroviral therapy–treated individuals impairs alveolar macrophage responses to pneumococci. Am J Respir Crit Care Med. 2018;197(12):1604–1615.
   PubMed Web of Science ®Google Scholar
• Jambo K, Banda D, Kankwatira A, et al. Small alveolar macrophages are infected preferentially by HIV and exhibit impaired phagocytic function. Mucosal Immunol. 2014;7:1116–1126.
   PubMed Web of Science ®Google Scholar
• Chinnapaiyan S, Parira T, Dutta R, et al. HIV infects bronchial epithelium and suppresses components of the mucociliary clearance apparatus. PloS One. 2017;12(1):e0169161.
   PubMed Web of Science ®Google Scholar
• Levine AM, Karim R, Mack W, et al. Neutropenia in human immunodeficiency virus infection: data from the women’s interagency HIV study. Arch Internal Med. 2006;166(4):405–410.
   PubMedGoogle Scholar
• Ellis M, Gupta S, Galant S, et al. Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. J Infect Dis. 1988;158(6):1268–1276.
   PubMed Web of Science ®Google Scholar
• Cordero E, Pachón J, Rivero A, et al. Haemophilus influenzae pneumonia in human immunodeficiency virus-infected patients. Clinl Infect Dis. 2000;30(3):461–465.
   PubMed Web of Science ®Google Scholar
• Schleicher GK, Hopley MJ, Feldman C. CD4 T-lymphocyte subset counts in HIV-seropositive patients during the course of community-acquired pneumonia caused by Streptococcus pneumoniae. Clin Microbiol Infect. 2004;10(6):587–589.
   PubMed Web of Science ®Google Scholar
• Chou SH, Prabhu SJ, Crothers K, et al. Thoracic diseases associated with HIV infection in the era of antiretroviral therapy: clinical and imaging findings. Radiographics. 2014;34(4):895–911.
   PubMed Web of Science ®Google Scholar
• Cordero E, Pachon J, Rivero A, et al. Usefulness of sputum culture for diagnosis of bacterial pneumonia in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21(5):362–367.
   PubMed Web of Science ®Google Scholar
• Lu Y, Ling G, Qiang C, et al. PCR diagnosis of pneumocystis pneumonia: a bivariate meta-analysis. J Clin Microbiol. 2011;49(12):4361–4363.
   PubMed Web of Science ®Google Scholar
• Worodria W, Davis JL, Cattamanchi A, et al. Bronchoscopy is useful for diagnosing smear-negative tuberculosis in HIV-infected patients. Eur Respir J. 2010;36(2):446–448.
   PubMed Web of Science ®Google Scholar
• Cattamanchi A, Ssewenyana I, Nabatanzi R, et al. Bronchoalveolar lavage enzyme-linked immunospot for diagnosis of smear-negative tuberculosis in HIV-infected patients. PloS One. 2012;7(6):e39838.
   PubMed Web of Science ®Google Scholar
• Afessa B, Morales I, Weaver B. Bacteremia in hospitalized patients with human immunodeficiency virus: A prospective, cohort study. BMC Infect Dis. 2001;1:13.
   PubMed Web of Science ®Google Scholar
• Boulware DR, Daley CL, Merrifield C, et al. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect. 2007;55(4):300–309.
   PubMed Web of Science ®Google Scholar
• Mercante JW, Winchell JM. Current and emerging legionella diagnostics for laboratory and outbreak investigations. Clin Microbiol Rev. 2015;28:95–133.
   PubMed Web of Science ®Google Scholar
• Parente DM, Cunha CB, Mylonakis E, et al. The clinical utility of methicillin-resistant staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications. Clin Infect Dis. 2018;67(1):1–7.
   PubMed Web of Science ®Google Scholar
• Mendelson F, Griesel R, Tiffin N, et al. C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study. BMC Infect Dis. 2018;18(1):399.
   PubMedGoogle Scholar
• Rasmussen TA, Sogaard OS, Camara C, et al. Serum procalcitonin in pulmonary tuberculosis. Int J Tuberculosis Lung Dis. 2011;15(2):251–256.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:Cd007498.
   PubMedGoogle Scholar
• Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95–107.
   PubMed Web of Science ®Google Scholar
• Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018;379(3):236–249.
   PubMed Web of Science ®Google Scholar
• Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberculosis Lung Dis. 2006;10(5):510–515.
   PubMed Web of Science ®Google Scholar
• Tokman S, Barnett CF, Jarlsberg LG, et al. Procalcitonin predicts mortality in HIV-infected Ugandan adults with lower respiratory tract infections. Respirology. 2014;19(3):382–388.
   PubMed Web of Science ®Google Scholar
• Schleicher GK, Herbert V, Brink A, et al. Procalcitonin and C-reactive protein levels in HIV-positive subjects with tuberculosis and pneumonia. Eur Respir J. 2005;25(4):688.
   PubMed Web of Science ®Google Scholar
• Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA. 2015;313(7):677–686.
   PubMed Web of Science ®Google Scholar
• Curran A, Falco V, Crespo M, et al. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome. HIV Med. 2008;9(8):609–615.
   PubMed Web of Science ®Google Scholar
• Chew KW, Yen IH, Li JZ, et al. Predictors of pneumonia severity in HIV-infected adults admitted to an Urban public hospital. AIDS Patient Care STDS. 2011;25(5):273–277.
   PubMed Web of Science ®Google Scholar
• Sanders KM, Marras TK, Chan CK. Pneumonia Severity Index in the Immunocompromised. Can Respir J. 2006;13(2):89–93.
   PubMedGoogle Scholar
• Almeida A, Almeida AR, Castelo Branco S, et al. CURB-65 and other markers of illness severity in community-acquired pneumonia among HIV-positive patients. Int J STD AIDS. 2016;27(11):998–1004.
   PubMed Web of Science ®Google Scholar
• Justice AC, Modur SP, Tate JP, et al. Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr. 2013;62(2):149–163.
   PubMed Web of Science ®Google Scholar
• Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563–572.
   PubMed Web of Science ®Google Scholar
• Barakat LA, Juthani-Mehta M, Allore H, et al. Comparing clinical outcomes in HIV-infected and uninfected older men hospitalized with community-acquired pneumonia. HIV Med. 2015;16(7):421–430.
   PubMed Web of Science ®Google Scholar
• Birkhamshaw E, Waitt CJ, Innes M, et al. Severity assessment of lower respiratory tract infection in Malawi: derivation of a novel index (SWAT-Bp) which outperforms CRB-65. PloS One. 2013;8(12):e82178.
   PubMed Web of Science ®Google Scholar
• Koss CA, Jarlsberg LG, Den Boon S, et al. A clinical predictor score for 30 day mortality among HIV-infected adults hospitalized with pneumonia in Uganda. PloS One. 2015;10(5):e0126591.
   PubMed Web of Science ®Google Scholar
• Millman AJ, Greenbaum A, Walaza S, et al. Development of a respiratory severity score for hospitalized adults in a high HIV-prevalence setting-South Africa, 2010–2011. BMC Pulm Med. 2017;17(1):28.
   PubMedGoogle Scholar
• Feldman C, Klugman KP, Yu VL, et al. Bacteraemic pneumococcal pneumonia: impact of HIV on clinical presentation and outcome. J Infect. 2007;55(2):125–135.
   PubMed Web of Science ®Google Scholar
• Madeddu G, Porqueddu EM, Cambosu F, et al. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era. Infection. 2008;36(3):231–236.
   PubMed Web of Science ®Google Scholar
• Madeddu G, Laura Fiori M, Stella Mura M. Bacterial community-acquired pneumonia in HIV-infected patients. Curr Opin Pulm Med. 2010;16(3):201–207.
   PubMed Web of Science ®Google Scholar
• Christensen D, Feldman C, Rossi P, et al. HIV infection does not influence clinical outcomes in hospitalized patients with bacterial community-acquired pneumonia: results from the capo international cohort study. Clinl Infect Dis. 2005;41(4):554–556.
   PubMed Web of Science ®Google Scholar
• AIDSINFO. Bacterial respiratory disease 2013 [ updated 2013 May 7; 2018 Oct 1]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/327/bacterial-respiratory
   Google Scholar
• Lodise TP, Kwa A, Cosler L, et al. Comparison of β-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized veterans affairs patients with community-acquired pneumonia. Antimicrob Agents Chemother. 2007;51(11):3977–3982.
   PubMed Web of Science ®Google Scholar
• García Vázquez E, Mensa J, Martínez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis. 2005;24(3):190–195.
   PubMed Web of Science ®Google Scholar
• Garin N, Genné D, Carballo S, et al. Β-lactam monotherapy vs β-lactam–macrolide combination treatment in moderately severe community-acquired pneumonia: A randomized noninferiority trial. JAMA Intern Med. 2014;174(12):1894–1901.
   PubMed Web of Science ®Google Scholar
• Postma DF, van Werkhoven CH, van Elden LJR, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med. 2015;372(14):1312–1323.
   PubMed Web of Science ®Google Scholar
• Figueiredo-Mello C, Naucler P, Negra MD, et al. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial. Clin Microbiol Infect. 2018;24(2):146–151.
   PubMed Web of Science ®Google Scholar
• Oosterheert JJ, Bonten MJM, Schneider MME, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ. 2006;333(7580):1193.
   PubMedGoogle Scholar
• Long R, Chong H, Hoeppner V, et al. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis. 2009;48(10):1354–1360.
   PubMed Web of Science ®Google Scholar
• Cheng Y-J, Nie X-Y, Chen X-M, et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol. 2015;66(20):2173–2184.
   PubMed Web of Science ®Google Scholar
• Reinsch N, Buhr C, Krings P, et al. Prevalence and risk factors of prolonged QTc interval in HIV-infected patients: results of the HIV-HEART study. HIV Clin Trials. 2009;10(4):261–268.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014;311(21):2199–2208.
   PubMed Web of Science ®Google Scholar
• Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12:Cd007720.
   PubMedGoogle Scholar
• Franzetti F, Grassini A, Piazza M, et al. Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection. 2006;34(1):9–16.
   PubMed Web of Science ®Google Scholar
• Feldman C, Anderson R. HIV-associated bacterial pneumonia. Clin Chest Med. 2013;34(2):205–216.
   PubMed Web of Science ®Google Scholar
• Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis. 2004;38(11):1623–1628.
   PubMed Web of Science ®Google Scholar
• Rizzi EB, Schinina V, Rovighi L, et al. HIV-related pneumococcal lung disease: does highly active antiretroviral therapy or bacteremia modify radiologic appearance? AIDS Patient Care STDS. 2008;22(2):105–111.
   PubMed Web of Science ®Google Scholar
• Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995–2000. J Infect Dis. 2005;191(12):2038–2045.
   PubMed Web of Science ®Google Scholar
• Bordon JM, Fernandez-Botran R, Wiemken TL, et al. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection. 2015;43(6):729–738.
   PubMed Web of Science ®Google Scholar
• Gaskell KM, Feasey NA, Heyderman RS. Management of severe non-TB bacterial infection in HIV-infected adults. Expert Rev Anti Infect Ther. 2015;13(2):183–195.
   PubMed Web of Science ®Google Scholar
• Felmingham D, Reinert RR, Hirakata Y, et al. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother. 2002;50(Suppl S1):25–37.
   PubMedGoogle Scholar
• Wierzbowski AK, Karlowsky JA, Adam HJ, et al. Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008. J Antimicrob Chemother. 2014;69(1):59–66.
   PubMed Web of Science ®Google Scholar
• Cilloniz C, Albert RK, Liapikou A, et al. The effect of macrolide resistance on the presentation and outcome of patients hospitalized for streptococcus pneumoniae pneumonia. Am J Respir Crit Care Med. 2015;191(11):1265–1272.
   PubMed Web of Science ®Google Scholar
• Steinhart R, Reingold AL, Taylor F, et al. Invasive haemophilus influenzae infections in men with hiv infection. JAMA. 1992;268(23):3350–3352.
   PubMed Web of Science ®Google Scholar
• Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. J Acquir Immune Defic Syndr. 2005;40(2):155–160.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Tacconelli E, Lucia MB, et al. Predictors of Staphylococcus aureus pneumonia associated with human immunodeficiency virus infection. Respir Med. 1996;90(9):531–537.
   PubMed Web of Science ®Google Scholar
• Domingo P, Ferre A, Baraldes M, et al. Pseudomonas aeruginosa bronchopulmonary infection in patients with AIDS, with emphasis on relapsing infection. Eur Respir J. 1998;12(1):107–112.
   PubMed Web of Science ®Google Scholar
• Head BM, Trajtman A, Rueda ZV, et al. Atypical bacterial pneumonia in the HIV-infected population. Pneumonia. 2017;9:12.
   Web of Science ®Google Scholar
• Pedro-Botet ML, Sabrià M, Sopena N, et al. Legionnaires disease and HIV infection. Chest. 2003;124(2):543–547.
   PubMed Web of Science ®Google Scholar
• Benitez AJ, Winchell JM. Clinical application of a multiplex real-time PCR assay for simultaneous detection of legionella species, legionella pneumophila, and legionella pneumophila serogroup 1. J Clin Microbiol. 2013;51(1):348–351.
   PubMed Web of Science ®Google Scholar
• Baron EJ, Miller JM, Weinstein MP, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2013 recommendations by the infectious diseases society of America (IDSA) and the American society for microbiology (ASM)(a). Clin Infect Dis. 2013;57(4):e22–e121.
   PubMed Web of Science ®Google Scholar
• Lamas CC, Coelho LE, Grinsztejn BJ, et al. Community-acquired lower respiratory tract infections in HIV-infected patients on antiretroviral therapy: predictors in a contemporary cohort study. Infection. 2017;45(6):801–809.
   PubMed Web of Science ®Google Scholar
• Lee KY, Tsai MS, Kuo KC, et al. Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy. Hum Vaccin Immunother. 2014;10(12):3700–3710.
   PubMed Web of Science ®Google Scholar
• Leads from the MMWR. JAMA. 1989;261(9):1265–1267.
   PubMedGoogle Scholar
• Rodriguez-Barradas MC, Serpa JA, Munjal I, et al. Quantitative and qualitative antibody responses to immunization with the pneumococcal polysaccharide vaccine in HIV-infected patients after initiation of antiretroviral treatment: results from a randomized clinical trial. J Infect Dis. 2015;211(11):1703–1711.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis. 2008;46(7):1093–1100.
   PubMed Web of Science ®Google Scholar
• Grau I, Pallares R, Tubau F, et al. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy. Arch Internal Med. 2005;165(13):1533–1540.
   PubMedGoogle Scholar
• Imaz A, Falco V, Penaranda M, et al. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease. HIV Med. 2009;10(6):356–363.
   PubMed Web of Science ®Google Scholar
• Hung CC, Chang SY, Su CT, et al. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med. 2010;11(1):54–63.
   PubMed Web of Science ®Google Scholar
• Kerneis S, Launay O, Turbelin C, et al. Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis. 2014;58(8):1130–1139.
   PubMed Web of Science ®Google Scholar
• Tasker SA, Wallace MR, Rubins JB, et al. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clinl Infect Dis. 2002;34(6):813–821.
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter LM, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet. 2000;355(9221):2106–2111.
   PubMed Web of Science ®Google Scholar
• Watera C, Nakiyingi J, Miiro G, et al. 23-Valent pneumococcal polysaccharide vaccine in HIV-infected Ugandan adults: 6-year follow-up of a clinical trial cohort. AIDS. 2004;18(8):1210–1213.
   PubMed Web of Science ®Google Scholar
• 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Releve Epidemiologique Hebdomadaire. 2008;83(42):373–384.
   PubMedGoogle Scholar
• French N, Gordon SB, Mwalukomo T, et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med. 2010;362(9):812–822.
   PubMed Web of Science ®Google Scholar
• Lesprit P, Pedrono G, Molina JM, et al. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults. AIDS. 2007;21(18):2425–2434.
   PubMed Web of Science ®Google Scholar
• Cheng A, Chang SY, Tsai MS, et al. Long-term immune responses and comparative effectiveness of one or two doses of 7-valent pneumococcal conjugate vaccine (PCV7) in HIV-positive adults in the era of combination antiretroviral therapy. J Int AIDS Soc. 2016;19(1):20631.
   PubMedGoogle Scholar
• Glesby MJ, Watson W, Brinson C, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with pneumococcal polysaccharide vaccine. J Infect Dis. 2015;212(1):18–27.
   PubMed Web of Science ®Google Scholar
• Bhorat AE, Madhi SA, Laudat F, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination. AIDS. 2015;29(11):1345–1354.
   PubMed Web of Science ®Google Scholar
• Rossheim AE, Young AM, Siik J, et al. Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults. Hum Vaccin Immunother. 2016;12(8):2117–2123.
   PubMed Web of Science ®Google Scholar
• Centers for Disease C, Prevention. CDC: use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the advisory committee on immunization practices (ACIP). MMWR. 2012;61(40):816–819.
   PubMedGoogle Scholar
• Iyer AS, Leggat DJ, Ohtola JA, et al. Response to pneumococcal polysaccharide vaccination in HIV-positive individuals on long term highly active antiretroviral therapy. J AIDS Clin Res. 2015;6:2.
   Google Scholar
• Lesourd A, Leporrier J, Delbos V, et al. Antiretroviral therapy as prevention of … pneumococcal infections? Open Forum Infect Dis. 2016;3(4):ofw228–ofw228.
   PubMedGoogle Scholar
• EACS. EACS guidelines. 2017 [ updated 2017 Oct; cited 2018 Feb 19/18]. Available from: http://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.html
   Google Scholar
• DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371(7):635–645.
   PubMed Web of Science ®Google Scholar
• Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices - United States, 2017–18 influenza season. MMWR Recomm Rep. 2017;66(2):1–20.
   PubMed Web of Science ®Google Scholar
• McKittrick N, Frank I, Jacobson JM, et al. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med. 2013;158(1):19–26.
   PubMed Web of Science ®Google Scholar
• Hirschtick RE, Glassroth J, Jordan MC, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus pulmonary complications of HIV infection study group. New Engl J Med. 1995;333(13):845–851.
   PubMed Web of Science ®Google Scholar
• Currier JS, Williams P, Feinberg J, et al. Impact of prophylaxis for Mycobacterium avium complex on bacterial infections in patients with advanced human immunodeficiency virus disease. Clin Infect Dis. 2001;32(11):1615–1622.
   PubMed Web of Science ®Google Scholar
• Sogaard OS, Lohse N, Gerstoft J, et al. Mortality after hospitalization for pneumonia among individuals with HIV, 1995–2008: a Danish cohort study. PloS One. 2009;4(9):e7022.
   PubMed Web of Science ®Google Scholar
• The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count–guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis. 2006;43(1):90–98.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015; 373(9):795–807.
   PubMed Web of Science ®Google Scholar
• Gritz ER, Danysh HE, Fletcher FE, et al. Long-term outcomes of a cell phone-delivered intervention for smokers living with HIV/AIDS. Clin Infect Dis. 2013;57(4):608–615.
   PubMed Web of Science ®Google Scholar
• Humfleet GL, Hall SM, Delucchi KL, et al. A randomized clinical trial of smoking cessation treatments provided in HIV clinical care settings. Nicotine Tob Res. 2013;15(8):1436–1445.
   PubMed Web of Science ®Google Scholar
• Pool ER, Dogar O, Lindsay RP, et al. Interventions for tobacco use cessation in people living with HIV and AIDS. Cochrane Database Syst Rev. 2016;13(6):Cd011120.
   Google Scholar
• Mercie P, Arsandaux J, Katlama C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. Lancet HIV. 2018;5(3):e126–e135.
   PubMed Web of Science ®Google Scholar